Fennec Pharmaceuticals Inc. commercializes PEDMARK, a sodium thiosulfate injection approved by the FDA as the first and only therapy to reduce the risk of ototoxicity from cisplatin in pediatric patients with localized, non-metastatic solid tumors. The company is a specialty pharmaceutical business that licensed the underlying technology exclusively from Oregon Health & Science University. Its sole marketed product addresses hearing protection in children undergoing platinum-based chemotherapy.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 8.8 | — | -1.2 | — |
| Q2 2025 | 9.7 | — | -3.1 | — |
| Q3 2025 | 12.5 | — | -0.6 | — |
| Q4 2025 | 13.8 | — | -4.8 | — |
| Q1 2026 | 15.1 | 72.6% | 0.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Global Indemnity Group, LLC (GBLI), Solowin Holdings (AXG), Talon Capital Corp. (TLNC), KRAKacquisition Corp. (KRAQ), Bank of Marin Bancorp (BMRC), Compass Therapeutics, Inc. (CMPX)